Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...
Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development
Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...
Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...
Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...
Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...
Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant
Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...
Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy
A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A...
Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive...
Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...
Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury
Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...
Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...
Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...